{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T15:11:36Z","timestamp":1668179496065},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13365-016-0494-8","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T11:24:32Z","timestamp":1480332272000},"page":"260-272","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Greater decline in memory and global neurocognitive function in HIV\/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin"],"prefix":"10.1007","volume":"23","author":[{"given":"Theodore R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Br\u00e4u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Stivala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Rivera-Mindt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"494_CR1","volume-title":"BDI-fast screen for medical patients: manual","author":"BT Aaron","year":"2000","unstructured":"Aaron BT (2000) BDI-fast screen for medical patients: manual. The Psychological Corporation, San Antonio, TX"},{"key":"494_CR2","doi-asserted-by":"crossref","unstructured":"Asnis GM, 2nd dela Garza R, Miller AH (2004) Ribavirin may be an important factor in IFN-induced neuropsychiatric effects.","DOI":"10.4088\/JCP.v65n0420b"},{"key":"494_CR3","doi-asserted-by":"crossref","unstructured":"Averhoff, G (2012) Global burden of hepatitis C: considerations for healthcare providers in the United States. doi:10.1093\/cid\/cis361","DOI":"10.1093\/cid\/cis361"},{"issue":"6","key":"494_CR4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.13514","volume":"43","author":"D Banerjee","year":"2016","unstructured":"Banerjee D, Reddy KR (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 43(6):674\u2013696","journal-title":"Aliment Pharmacol Ther"},{"key":"494_CR5","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer B (1996) Beck depression inventory-II.","DOI":"10.1037\/t00742-000"},{"key":"494_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12254-016-0269-1","volume":"9","author":"J-P Bohn","year":"2016","unstructured":"Bohn J-P, Gastl G, Steurer M (2016) Long-term treatment of hairy cell leukemia with interferon-\u03b1: still a viable therapeutic option. Memo 9:63\u201365. doi: 10.1007\/s12254-016-0269-1","journal-title":"Memo"},{"key":"494_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/13854049108403297","volume":"5","author":"J Brandt","year":"1991","unstructured":"Brandt J (1991) The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin Neuropsychol 5:125\u2013142. doi: 10.1080\/13854049108403297","journal-title":"Clin Neuropsychol"},{"key":"494_CR8","doi-asserted-by":"crossref","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ (2014) Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.","DOI":"10.1016\/S1474-4422(14)70068-7"},{"key":"494_CR9","doi-asserted-by":"publisher","first-page":"561570","DOI":"10.1007\/s13365-014-0265-3","volume":"20","author":"J Cattie","year":"2014","unstructured":"Cattie J, Letendre S, Woods S, Barakat F, Perry W, Cherner M et al (2014) Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. Journal of NeuroVirology 20:561570. doi: 10.1007\/s13365-014-0265-3","journal-title":"Journal of NeuroVirology"},{"issue":"2","key":"494_CR10","volume":"3","author":"L Cha","year":"2014","unstructured":"Cha L, Berry CM, Nolan D, Castley A, Fernandez S, French MA (2014) Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clinical & Translational Immunology 3(2):e10","journal-title":"Clinical & Translational Immunology"},{"key":"494_CR11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/ene.12317","volume":"21","author":"W-C Chiu","year":"2014","unstructured":"Chiu W-C, Tsan Y-T, Tsai S-L et al (2014) Hepatitis C viral infection and the risk of dementia. European journal of neurology\u00a0: the official journal of the European Federation of Neurological Societies 21:1068\u20131e59. doi: 10.1111\/ene.12317","journal-title":"European journal of neurology\u00a0: the official journal of the European Federation of Neurological Societies"},{"key":"494_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200510003-00011","author":"DB Clifford","year":"2005","unstructured":"Clifford DB, Evans SR, Yang Y, Gulick RM (2005) The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. doi: 10.1097\/00002030-200510003-00011","journal-title":"AIDS"},{"key":"494_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/13803395.2010.535504","author":"LA Cysique","year":"2011","unstructured":"Cysique LA, Franklin D Jr, Abramson I (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. doi: 10.1080\/13803395.2010.535504","journal-title":"J Clin Exp Neuropsychol"},{"key":"494_CR14","doi-asserted-by":"crossref","unstructured":"Dieperink, W (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review.","DOI":"10.1176\/appi.ajp.157.6.867"},{"key":"494_CR15","doi-asserted-by":"crossref","unstructured":"Fontana RJ, Bieliauskas LA, Back-Madruga C (2010) Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.","DOI":"10.1038\/ajg.2010.3"},{"key":"494_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21633","author":"RJ Fontana","year":"2007","unstructured":"Fontana RJ, Bieliauskas LA, Lindsay KL (2007) Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepathology. doi: 10.1002\/hep.21633","journal-title":"Hepathology"},{"key":"494_CR17","doi-asserted-by":"crossref","unstructured":"Forton, T-R (2006) Central nervous system changes in hepatitis C virus infection.","DOI":"10.1097\/00042737-200604000-00005"},{"key":"494_CR18","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30688","author":"DM Forton","year":"2002","unstructured":"Forton DM, Thomas HC, Murphy CA, Allsop JM (2002) Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepathology. doi: 10.1053\/jhep.2002.30688","journal-title":"Hepathology"},{"key":"494_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360730","author":"MW Fried","year":"2002","unstructured":"Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepathology. doi: 10.1002\/hep.1840360730","journal-title":"Hepathology."},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00126334-200402010-00005","volume":"35","author":"H-J Giesen","year":"2004","unstructured":"Giesen H-J, Heintges T, Abbasi-Boroudjeni N et al (2004) Psychomotor slowing in hepatitis C and HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:131\u2013137. doi: 10.1097\/00126334-200402010-00005","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"494_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11904-014-0210-3","volume":"11","author":"A Gill","year":"2014","unstructured":"Gill A, Kolson D (2014) Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Current HIV\/AIDS reports 11:325\u2013335. doi: 10.1007\/s11904-014-0210-3","journal-title":"Current HIV\/AIDS reports"},{"key":"494_CR22","unstructured":"Heaton RK, Kirson D, Velin RA, Grant I (1994) The utility of clinical ratings for detecting cognitive change in HIV infection."},{"key":"494_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318200d727","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr, Woods SP (2010a) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurology. doi: 10.1212\/WNL.0b013e318200d727","journal-title":"Neurology"},{"key":"494_CR24","doi-asserted-by":"crossref","unstructured":"Heaton RK, Franklin DR, Deutsch R, et al (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. doi: 10.1093\/cid\/ciu862","DOI":"10.1093\/cid\/ciu862"},{"key":"494_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13365-010-0006-1","volume":"17","author":"R Heaton","year":"2010","unstructured":"Heaton R, Franklin D, Ellis R et al (2010b) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology 17:3\u201316. doi: 10.1007\/s13365-010-0006-1","journal-title":"Journal of NeuroVirology"},{"key":"494_CR26","doi-asserted-by":"crossref","unstructured":"Hilsabeck, C (2005a) Neuropsychological aspects of coinfection with HIV and hepatitis C virus. doi: 10.1086\/429494","DOI":"10.1086\/429494"},{"key":"494_CR27","doi-asserted-by":"crossref","unstructured":"Hilsabeck, H (2005b) Effect of Interferon-[alpha] on cognitive functioning in patients with chronic hepatitis C.","DOI":"10.1017\/S1355617705050022"},{"key":"494_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/jhep.2002.31257","volume":"35","author":"R Hilsabeck","year":"2002","unstructured":"Hilsabeck R, Perry W, Hassanein T (2002) Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35:440\u2013446. doi: 10.1053\/jhep.2002.31257","journal-title":"Hepatology"},{"key":"494_CR29","unstructured":"Hinkin CH, Aronow HA, Hilsabeck RC (2004) Psychiatric and cognitive concomitants of HIV and HCV co-infection. In: National Institute on Drug Abuse (NIDA) symposium on issues in the medical management of HIV\/HCV co-infection in IDUs (Washington, DC)."},{"key":"494_CR30","doi-asserted-by":"publisher","DOI":"10.1300\/J069v27n02_02","author":"CH Hinkin","year":"2008","unstructured":"Hinkin CH, Castellon SA, Levine AJ (2008) Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. doi: 10.1300\/J069v27n02_02","journal-title":"J Addict Dis"},{"key":"494_CR31","doi-asserted-by":"crossref","unstructured":"Hinton-Bayre AD (2010a) Deriving reliable change statistics from test\u2013retest normative data: comparison of models and mathematical expressions.","DOI":"10.1093\/arclin\/acq008"},{"key":"494_CR32","doi-asserted-by":"crossref","unstructured":"Hinton-Bayre AD (2010b) Specificity of reliable change models and review of the within-subjects standard deviation as an error term. doi: 10.1093\/arclin\/acq087","DOI":"10.1093\/arclin\/acq087"},{"key":"494_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpsychores.2014.07.020","volume":"78","author":"M Huckans","year":"2015","unstructured":"Huckans M, Fuller B, Wheaton V et al (2015) A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res 78:184\u2013192","journal-title":"J Psychosom Res"},{"key":"494_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s13365-011-0032-7","volume":"17","author":"T Jernigan","year":"2011","unstructured":"Jernigan T, Archibald S, Fennema-Notestine C et al (2011) Clinical factors related to brain structure in HIV: the CHARTER study. Journal of neurovirology 17:248\u2013257. doi: 10.1007\/s13365-011-0032-7","journal-title":"Journal of neurovirology"},{"key":"494_CR35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008960710415","author":"L Kleinman","year":"2000","unstructured":"Kleinman L, Zodet MW, Hakim Z, Aledort J (2000) Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res. doi: 10.1023\/A:1008960710415","journal-title":"Qual Life Res"},{"key":"494_CR36","doi-asserted-by":"crossref","unstructured":"Koziel, P (2007) Viral hepatitis in HIV infection.","DOI":"10.1056\/NEJMra065142"},{"key":"494_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clpt.2004.09.007","volume":"77","author":"M Kraus","year":"2005","unstructured":"Kraus M, Sch\u00e4fer A, Wi\u00dfmann S et al (2005) Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clinical Pharmacology & Therapeutics 77:90\u2013100. doi: 10.1016\/j.clpt.2004.09.007","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"494_CR38","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCS.0000045348.28440.82","author":"DG Krefetz","year":"2004","unstructured":"Krefetz DG, Steer RA, Jermyn RT (2004) Screening HIV-infected patients with chronic pain for anxiety and mood disorders with the Beck anxiety and depression inventory-fast screens for medical settings. J Clin Psychol Med Settings. doi: 10.1023\/B:JOCS.0000045348.28440.82","journal-title":"J Clin Psychol Med Settings"},{"key":"494_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J (1989) The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. doi: 10.1001\/archneur.1989.00520460115022","journal-title":"Arch Neurol"},{"key":"494_CR40","doi-asserted-by":"crossref","unstructured":"Lieb K, Engelbrecht MA, Gut O, et al (2006) Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN\u03b1): results from a prospective study.","DOI":"10.1016\/j.eurpsy.2004.09.030"},{"key":"494_CR41","doi-asserted-by":"crossref","unstructured":"Maassen GH (2010) The two errors of using the within-subject standard deviation (WSD) as the standard error of a reliable change index. doi: 10.1093\/arclin\/acq036","DOI":"10.1093\/arclin\/acq036"},{"key":"494_CR42","doi-asserted-by":"crossref","unstructured":"Majer, WL, Capuron, P (2008) IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.","DOI":"10.1016\/j.bbi.2007.12.009"},{"key":"494_CR43","doi-asserted-by":"crossref","unstructured":"Martin EM, Novak RM, Fendrich M (2004) Stroop performance in drug users classified by HIV and hepatitis C virus serostatus.","DOI":"10.1017\/S135561770410218X"},{"key":"494_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/hep.20635","volume":"41","author":"M McAndrews","year":"2005","unstructured":"McAndrews M, Farcnik K, Carlen P et al (2005) Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology (Baltimore, Md) 41:801\u2013808. doi: 10.1002\/hep.20635","journal-title":"Hepatology (Baltimore, Md)"},{"key":"494_CR45","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Gordon SC, Schiff ER (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","DOI":"10.1056\/NEJM199811193392101"},{"key":"494_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/13854049308401901","author":"JA McSweeny","year":"1993","unstructured":"McSweeny JA, Naugle RI, Chelune GJ (1993) \u201cT scores for change\u201d: an illustration of a regression approach to depicting change in clinical neuropsychology. Clinical Neuropsychologist. doi: 10.1080\/13854049308401901","journal-title":"Clinical Neuropsychologist"},{"key":"494_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/08964289.2014.914464","volume":"40","author":"M Mindt","year":"2014","unstructured":"Mindt M, Miranda C, Arentoft A et al (2014) Aging and HIV\/AIDS: neurocognitive implications for older HIV-positive Latina\/o adults. Behav Med 40:116\u2013123. doi: 10.1080\/08964289.2014.914464","journal-title":"Behav Med"},{"key":"494_CR48","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","volume":"33","author":"P Mohr","year":"2015","unstructured":"Mohr P, Hauschild A, Trefzer U et al (2015) Intermittent high-dose intravenous interferon Alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III dermatologic cooperative oncology group trial. J Clin Oncol 33:4077\u20134084. doi: 10.1200\/JCO.2014.59.6932","journal-title":"J Clin Oncol"},{"key":"494_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2013.11.021","volume":"23","author":"C Mosa","year":"2014","unstructured":"Mosa C, Trizzino A, Trizzino A et al (2014) Treatment of human papillomavirus infection with interferon alpha and ribavirin in a patient with acquired aplastic anemia. Int J Infect Dis 23:25\u201327. doi: 10.1016\/j.ijid.2013.11.021","journal-title":"Int J Infect Dis"},{"key":"494_CR50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1590\/S1413-86702007000300017","volume":"11","author":"MH Pavan","year":"2007","unstructured":"Pavan MH, Velho PE, Vigani AG et al (2007) Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin. Braz J Infect Dis 11:383\u2013384","journal-title":"Braz J Infect Dis"},{"key":"494_CR51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.genhosppsych.2008.03.001","volume":"30","author":"T Pawelczyk","year":"2008","unstructured":"Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-Jablonska J (2008) Pegylated interferon and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen Hosp Psychiatry 30:501\u2013508","journal-title":"Gen Hosp Psychiatry"},{"key":"494_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200510003-00013","author":"W Perry","year":"2005","unstructured":"Perry W, Carlson MD, Barakat F, Hilsabeck RC (2005) Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. doi: 10.1097\/00002030-200510003-00013","journal-title":"AIDS"},{"key":"494_CR53","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard T, Marcellin P, Lee S et al (1998) Randomised trial of interferon 2b plus ribavirin for 48\u00a0weeks or for 24\u00a0weeks versus interferon 2b plus placebo for 48\u00a0weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426\u20131432","journal-title":"Lancet"},{"issue":"Suppl 3","key":"494_CR54","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1097\/01.aids.0000192087.64432.ae","volume":"19","author":"A Reichenberg","year":"2005","unstructured":"Reichenberg A, Gorman J, Dieterich D (2005) Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72\u00a0week prospective study. AIDS (London, England) 19(Suppl 3):S174\u2013S178","journal-title":"AIDS (London, England)"},{"key":"494_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000115177.74976.6C","author":"EL Ryan","year":"2004","unstructured":"Ryan EL, Morgello S, Isaacs K et al (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. doi: 10.1212\/01.WNL.0000115177.74976.6C","journal-title":"Neurology"},{"key":"494_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21791","author":"M Schaefer","year":"2007","unstructured":"Schaefer M, Hinzpeter A, Mohmand A, Janssen G (2007) Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hpatology. doi: 10.1002\/hep.21791","journal-title":"Hpatology"},{"key":"494_CR57","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","volume":"26","author":"M Schaefer","year":"2002","unstructured":"Schaefer M, Engelbrechta M, Gut O et al (2002) Interferon alpha (IFN) and psychiatric syndromes: a review. Prog Neuro-Psychopharmacol Biol Psychiatry 26:731\u2013746","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"494_CR58","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1086\/653428","volume":"51","author":"NK Shrestha","year":"2010","unstructured":"Shrestha NK, Hamrock DJ (2010) Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin. Clin Infect Dis 51:e4\u2013e6. doi: 10.1086\/653428","journal-title":"Clin Infect Dis"},{"key":"494_CR59","unstructured":"Statistical Package for Social Sciences for Windows, Version 22.0. Chicago, Illinois. 2015."},{"key":"494_CR60","doi-asserted-by":"crossref","unstructured":"Tanaka, M, Shigekawa, U (2006) Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: a preliminary study. doi: 10.1007\/s10238\u2013006\u20130107-6","DOI":"10.1007\/s10238-006-0107-6"},{"key":"494_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e6d51","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. doi: 10.1097\/QAD.0b013e32830e6d51","journal-title":"AIDS"},{"key":"494_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00452.x","author":"H Thein","year":"2007","unstructured":"Thein H, Maruff P, Krahn M, Kaldor J (2007) Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV\/HCV-coinfected individuals commencing HCV. HIV Med. doi: 10.1111\/j.1468-1293.2007.00452.x","journal-title":"HIV Med"},{"key":"494_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04004.x","author":"JJ Weiss","year":"2009","unstructured":"Weiss JJ, Br\u00e4u N, Stivala A, Swan T (2009) Review article: adherence to medication for chronic hepatitis C\u2013building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. doi: 10.1111\/j.1365-2036.2009.04004.x","journal-title":"Aliment Pharmacol Ther"},{"key":"494_CR64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","volume":"171","author":"I Williams","year":"2011","unstructured":"Williams I, Bell B, Kuhnert W, Alter M (2011) Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 171:242\u2013248. doi: 10.1001\/archinternmed.2010.511","journal-title":"Arch Intern Med"},{"key":"494_CR65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/15622970701714362","volume":"10","author":"T Wobrock","year":"2008","unstructured":"Wobrock T, Mihm U, L\u00f6hr C et al (2008) Cognition in hepatitis C patients treated with pegylated interferon. The world journal of biological psychiatry\u00a0: the official journal of the World Federation of Societies of Biological Psychiatry 10:819\u2013826. doi: 10.1080\/15622970701714362","journal-title":"The world journal of biological psychiatry\u00a0: the official journal of the World Federation of Societies of Biological Psychiatry"},{"key":"494_CR66","doi-asserted-by":"crossref","unstructured":"Woods, R, Frol, L (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. doi: 10.1080\/13803390490509565","DOI":"10.1080\/13803390490509565"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-016-0494-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T21:16:16Z","timestamp":1568582176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-016-0494-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1007\/s13365-016-0494-8","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}